Increasing Efficiency in Pharmaceutical Analysis by Using Enhanced Automation Techniques to Characterize Preclinical and Clinical Drug Candidates
Description:
Automation has been successfully used in quality control and discovery in the pharmaceutical industry for 30 years, or more. Yet its use in reliably testing chemical and physical properties of lead candidate drugs transitioning from discovery to development is less established. What’s needed in the pre-clinical and early clinical phases is to enhance our automation capability for identifying key property and quality attributes when evaluating development risks. For example, molecular properties like solubility, chemical and physical stability, impurities, and the impact these have on biopharmaceutics are investigated. The advances in drug discovery have led to an array of compounds that range from small molecules to structures like mRNAs and proteins making it even more important to quickly identify key method attributes.
While automation is a broad term that includes robotics for sample preparation, it also encompasses knowledge management concepts of data integration, evaluation, and result reporting. The purpose of this symposium will be to explore how we can gain speed and efficiency to assess development risks by using new automation tools and advanced analytical instrumentation.
Organizer: Stacey Marden - AstraZeneca
Biography: Stacey Marden is a senior analytical scientist at AstraZeneca with over 30 years’ experience in the pharmaceutical industry. She has been involved in all phases of pharmaceutical development and is currently working in the pre-clinical space. She greatly enjoys the scientific challenges encompassing new molecular entities and is tenacious to discover their hidden secrets. Stacey is a member of the AstraZeneca global Degradation Network and is actively involved in the International Forced Degradation Community (IFDC), a cross-pharma group whose purpose is to study and recommend best practices for performing forced degradation studies. Since finishing her PhD at the University of Massachusetts, she has held many roles over the years including project lead for compounds transitioning from discovery to development, group leader, and business lead for a departmental LIMS system. Personally, Stacey is an outdoor enthusiast and bird watcher, and enjoys cycling to work as often as possible.
Co-Organizer: Jenny Ottosson - AstraZeneca
Biography: Jenny Ottosson, with a motto ”we play to win”, is an Associate Principal Scientist in analytical science within Pharmaceutical Sciences at the AstraZeneca site in Mölndal Sweden. One main part is driving and take lead in improvements to progress the pharmaceutical projects. Current focus is setup of new automation capabilities aiming for efficiency for projects transferring from discovery into development and the early clinical phase. Jenny has worked in the field within the industrial pharmaceutical area for 21 years, spanning from early pre-clinical to late clinical Phase, and her strength is in separation science. Together with her educational background in material science and chemical engineering, and her extensive experience as a project manager, her knowledge of the early development phase is key for finding new ways to optimize early workflows. Apart from the technical skills, Jenny brings energy and strives for constant improvements in her work.
Speakers:
Christopher Welch - ICASE - Indiana Consortium for Analytical Sciences & Engineering
Mike Rerick - GSK
Ouyang Ouyang - Merck & Co
Dennis Leung - Genentech, Inc.
Jenny Ottosson - AstraZeneca
Speakers:
-
-
-
-
-
-
-
-
Speakers:
-
-
-
-
-
Speakers:
-
-
-
-
-
: -
Biography:
Course Outline:
Learning Objectives:
: -
Co-Authors:
-
-
-
-
-
-
-
-
-
-
: -
Co-Facilitator: -
Increasing Efficiency in Pharmaceutical Analysis by Using Enhanced Automation Techniques to Characterize Preclinical and Clinical Drug Candidates
Stacey Marden - AstraZeneca
Enhanced High Throughput Analysis and Property Prediction for Pharmaceutical Development
Christopher Welch - ICASE
Automated High-Sensitivity Biorelevant Solubility Workflow for Applications in Long-Acting Injectable Pharmaceutical Drug Development
Michael Rerick - GSK
Design, Execution and Analysis of High Throughput Biological Formulation Screening to Accelerate Drug Product Development
Hanlin Ouyang - Merck
Automation of sample preparation and sample management provides efficiency gains when evaluating developability of drug compounds
Jenny Ottosson - Advanced Drug Delivery, Pharmaceutical Sciences, Bio Pharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Finding Signal in the Noise: Visualizing Big Data to Design Better Drugs
Dennis Leung - Genentech, Inc.
Increasing Efficiency in Pharmaceutical Analysis by Using Enhanced Automation Techniques to Characterize Preclinical and Clinical Drug Candidates
Description
Session Number: S04-00
Session Type: Symposium
Session Date: Sunday 3/19/2023
Session Time: 8:30 AM - 11:45 AM
Room Number: 117
Track: Pharmaceutical
Category: Pharmaceutical/Biologics
Register for Pittcon 2023